The Firm has filed a class action lawsuit to recover hundreds of millions of dollars improperly paid as a result of the creation, maintenance, and concealment of a multi-tiered fraudulent scheme to deceive consumers and artificially restrain competition in connection with the marketing and sale of the EpiPen epinephrine injector. The suit names Pfizer, the manufacturer of the device, and Mylan, responsible for its marketing. By raising the Epipen price, selling the Epipen in two-packs, and cutting the expiration period in half, these sales practices make the Epipen cost prohibitive and too expensive for many consumers.
In re Mylan Epipen Litigation, Case No. 16-CV-2711-JWL (D. Kan. 2016).